ES2181396T3 - Inhibicion de la apoptosis independiente de cd95 en el sida. - Google Patents

Inhibicion de la apoptosis independiente de cd95 en el sida.

Info

Publication number
ES2181396T3
ES2181396T3 ES99907249T ES99907249T ES2181396T3 ES 2181396 T3 ES2181396 T3 ES 2181396T3 ES 99907249 T ES99907249 T ES 99907249T ES 99907249 T ES99907249 T ES 99907249T ES 2181396 T3 ES2181396 T3 ES 2181396T3
Authority
ES
Spain
Prior art keywords
inhibition
aids
independent apoptosis
binding
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99907249T
Other languages
English (en)
Inventor
Peter H Krammer
Christina Berndt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2181396T3 publication Critical patent/ES2181396T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Procedimiento para la inhibición in vitro de la apoptosis independiente de CD95, que comprende los pasos de procedimiento: (a) bloqueo de la unión de la gp120 de VIH-1 a los receptores CD4 y/o CXCR4 o de un factor que compite por esta unión, y/o (b) inhibición de la vía de señalización inducida por la unión de (a).
ES99907249T 1998-01-15 1999-01-15 Inhibicion de la apoptosis independiente de cd95 en el sida. Expired - Lifetime ES2181396T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19801265A DE19801265C1 (de) 1998-01-15 1998-01-15 Inhibierung von CD95-unabhängiger Apoptose bei AIDS

Publications (1)

Publication Number Publication Date
ES2181396T3 true ES2181396T3 (es) 2003-02-16

Family

ID=7854675

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99907249T Expired - Lifetime ES2181396T3 (es) 1998-01-15 1999-01-15 Inhibicion de la apoptosis independiente de cd95 en el sida.

Country Status (7)

Country Link
US (1) US6485929B1 (es)
EP (1) EP1049490B1 (es)
JP (1) JP2002509118A (es)
AT (1) ATE221389T1 (es)
DE (2) DE19801265C1 (es)
ES (1) ES2181396T3 (es)
WO (1) WO1999036091A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US6944901B2 (en) * 2002-09-27 2005-09-20 Colgate-Palmolive Company Brush section for a powered toothbrush
EP1942108B1 (en) 2005-10-28 2013-09-04 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2425001A4 (en) 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use

Also Published As

Publication number Publication date
ATE221389T1 (de) 2002-08-15
EP1049490A2 (de) 2000-11-08
WO1999036091A3 (de) 1999-09-16
DE19801265C1 (de) 1999-08-12
EP1049490B1 (de) 2002-07-31
DE59902180D1 (de) 2002-09-05
US6485929B1 (en) 2002-11-26
JP2002509118A (ja) 2002-03-26
WO1999036091A2 (de) 1999-07-22

Similar Documents

Publication Publication Date Title
AR025244A1 (es) Uso de inhibidores de monoamina oxidasa para la elaboracion de farmacos destinados al tratamiento de la obesidad
ES2081857T3 (es) Nuevos inhibidores de alpha-glucosidasa.
BR0113798A (pt) Derivados de resorcinol
TR200000782T2 (tr) Resorsinol türevleri.
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
ES2187200T3 (es) Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso.
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
AR025020A1 (es) Forma de administracion oral que contiene al menos una especie de microorganismos probioticos, y procedimiento para su preparacion
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ES2172680T3 (es) Ligante antagonista rar-gamma o agonista rar-alfa como inhibidor de apoptosis.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
GT200200235A (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2
BR0012291A (pt) Fenoxifluorpirimidinas
AR030721A1 (es) Agonistas del receptor tweak como agentes anti-angiogenicos
HN1999000196A (es) Derivados de indol
ES2162493T3 (es) Metodo para el combate de la obesidad.
DE59902180D1 (de) Inhibierung von cd95-unabhängiger apoptose bei aids
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
DK0841937T4 (da) Anvendelse af betaglycan til reduktion af ardannelse
CO5090889A1 (es) Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
ES2074410T3 (es) Procedimiento para la fabricacion de pletinas de chapa de acero soldadas.
WO2001070953A3 (en) Identification of modulators of the inteferon gamma signaling pathway and their use in restenosis treatment